AKBA
Akebia Therapeutics, Inc.
$0.9360
+0.11%
$246.8M
No data for this timeframe.
Vol
Market Cap$246.8M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (91%)
Inst. Holders8 funds
Inst. Value$43.1M
Inst. Activity3 buys / 1 sells
Insider Activity1B / 6S
Insider Net $-$205.0K
SEC Reports2
Recent Activity
Jun 1, 2026
other
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Trac
Apr 30, 2026
SEC
Akebia Therapeutics reported Q4 2025 EPS of $-0.05, a 900% miss vs consensus of $-0.01, with revenue of $51.7M in line w
PRESS-RELEASE — Impact 7/10
Apr 1, 2026
Insider
Vickers Philip J. sold 214,400 shares
Director @ $0.00 ($0.00)
Apr 1, 2026
Event
VAFSEO
Supplemental Approval — Labeling — VADADUSTAT — TABLET — ORAL
Mar 4, 2026
Insider
Butler John P. bought 69,270 shares
CEO and President @ $1.25 ($86.6K)
Feb 26, 2026
SEC
Akebia Therapeutics reported strong financial results for Q4 and full-year 2025, with total revenues of $57.6 million (Q
8-K — Impact 7/10
Feb 2, 2026
Insider
Grund Nicholas sold 53,585 shares
Chief Commercial Officer @ $1.39 ($74.5K)
Inst.
BANK OF AMERICA CORP — ADD
2,257,411 shares ($3.6M)
Price Targets
$4.20
+356.5% upside
Strong Buy
Current $0.9200
Low $3.00
Median $4.00
High $6.00
5 analysts
$3.00
$6.00
Analyst Ratings
5Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 7, 2026 | BTIG | REITERATE | Buy → Buy |
| Feb 25, 2026 | BTIG | MAINTAIN | Buy → Buy |
| Feb 6, 2026 | Piper Sandler | MAINTAIN | Overweight → Overweight |
| Feb 6, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.03 ▼ -400.0% | $-0.03 — $-0.02 | -194% YoY | 2 |
| Next Q | $-0.03 ▼ -700.0% | $-0.04 — $-0.02 | 0% YoY | 2 |
| Current FY | $-0.10 ▼ -800.0% | $-0.13 — $-0.08 | -425% YoY | 2 |
| Next FY | $-0.19 ▼ -100.0% | $-0.20 — $-0.18 | -81% YoY | 2 |
Latest Reports
BEARISH
PRESS-RELEASE
7/10
Akebia Therapeutics reported Q4 2025 EPS of $-0.05, a 900% miss vs consensus of $-0.01, with revenue of $51.7M in line w
Apr 30, 2026
BULLISH
8-K
7/10
Akebia Therapeutics reported strong financial results for Q4 and full-year 2025, with total revenues of $57.6 million (Q
Feb 26, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $25.8M | — |
| RENAISSANCE TECHNOLOGIES LLC | $5.8M | — |
| BANK OF AMERICA CORP | $3.6M | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $3.5M | DOUBLED |
| MORGAN STANLEY | $2.0M | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 1, 2026 | Vickers Philip | A | $0.00 |
| Mar 4, 2026 | Butler John | BUY | $86.6K |
| Feb 2, 2026 | Grund Nicholas | SELL | $74.5K |
| Feb 2, 2026 | Butler John | SELL | $64.9K |
| Feb 2, 2026 | Butler John | A | $247.1K |
8 institutional holders with $43.1M total value (26,778,650 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, BANK. Net buying activity: 3 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 16,016,448 | $25.8M | 59.8% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 3,593,133 | $5.8M | 13.4% | — |
| 3 | BANK OF AMERICA CORP /DE/ | 2,257,411 | $3.6M | 8.4% | ADD +26.2% |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2,180,820 | $3.5M | 8.1% | DOUBLED +189.8% |
| 5 | MORGAN STANLEY | 1,228,816 | $2.0M | 4.6% | TRIM -71.5% |
| 6 | FMR LLC | 1,125,638 | $1.8M | 4.2% | — |
| 7 | WELLS FARGO & COMPANY/MN | 285,765 | $460.1K | 1.1% | ADD +50.3% |
| 8 | TWO SIGMA INVESTMENTS, LP | 90,619 | $145.9K | 0.3% | NEW |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | ADD | 1,788,500 | 2,257,411 | +26.2% | $3.6M | 2025-Q4 |
| MORGAN STANLEY | TRIM | 4,315,201 | 1,228,816 | -71.5% | $2.0M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 190,089 | 285,765 | +50.3% | $460.1K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 90,619 | — | $145.9K | 2025-Q4 |
| UBS Group AG | DOUBLED | 639,462 | 3,646,233 | +470.2% | $10.0M | 2025-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | DOUBLED | 749,015 | 2,170,281 | +189.8% | $5.9M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 1,110,480 | 1,788,500 | +61.1% | $4.9M | 2025-Q3 |
| MORGAN STANLEY | ADD | 2,681,198 | 5,339,654 | +99.2% | $19.4M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 481,910 | 1,110,480 | +130.4% | $4.0M | 2025-Q2 |
| CITADEL ADVISORS LLC | DOUBLED | 1,495,346 | 3,832,609 | +156.3% | $7.4M | 2025-Q1 |
| MORGAN STANLEY | ADD | 1,790,051 | 2,681,198 | +49.8% | $5.1M | 2025-Q1 |
| UBS Group AG | ADD | 351,091 | 592,410 | +68.7% | $1.1M | 2025-Q1 |
| MORGAN STANLEY | ADD | 1,088,892 | 1,790,051 | +64.4% | $3.4M | 2024-Q4 |
| CITADEL ADVISORS LLC | DOUBLED | 198,700 | 1,495,346 | +652.6% | $2.8M | 2024-Q4 |
| UBS Group AG | DOUBLED | 153,662 | 351,091 | +128.5% | $667.1K | 2024-Q4 |
| MORGAN STANLEY | ADD | 763,332 | 1,088,892 | +42.6% | $1.4M | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 568,667 | — | $750.6K | 2024-Q3 |
7 unique insiders with 7 transactions. Net insider value: -$205.0K ($86.6K bought, $291.6K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 1, 2026 | Vickers Philip J. | Director | A | 214,400 | $0.00 | $0.00 |
| Mar 4, 2026 | Butler John P. | CEO and President | BUY | 69,270 | $1.25 | $86.6K |
| Feb 2, 2026 | Grund Nicholas | Chief Commercial Officer | SELL | 53,585 | $1.39 | $74.5K |
| Feb 2, 2026 | Butler John P. | CEO and President | SELL | 46,660 | $1.39 | $64.9K |
| Feb 2, 2026 | Butler John P. | CEO and President | A | 175,250 | $1.41 | $247.1K |
| Feb 2, 2026 | Malabre Richard C | SVP, Chief Accounting Officer | SELL | 36,142 | $1.39 | $50.2K |
| Feb 2, 2026 | Rucci Carolyn M. | SVP, Chief Legal Officer | SELL | 16,846 | $1.39 | $23.4K |
| Feb 2, 2026 | Ostrowski Erik | SVP, CFO, CBO & Treasurer | SELL | 34,951 | $1.39 | $48.6K |
| Feb 2, 2026 | Burke Steven Keith | SVP, Chief Medical Officer | SELL | 21,582 | $1.39 | $30.0K |
| Jan 30, 2026 | Burke Steven Keith | SVP, Chief Medical Officer | A | 204,000 | $0.00 | $0.00 |
| Jan 30, 2026 | Burke Steven Keith | SVP, Chief Medical Officer | A | 320,000 | $0.00 | $0.00 |
| Jan 30, 2026 | Ostrowski Erik | SVP, CFO, CBO & Treasurer | A | 204,000 | $0.00 | $0.00 |
| Jan 30, 2026 | Ostrowski Erik | SVP, CFO, CBO & Treasurer | A | 320,000 | $0.00 | $0.00 |
| Jan 30, 2026 | Rucci Carolyn M. | SVP, Chief Legal Officer | A | 190,000 | $0.00 | $0.00 |
| Jan 30, 2026 | Rucci Carolyn M. | SVP, Chief Legal Officer | A | 270,000 | $0.00 | $0.00 |
| Jan 30, 2026 | Malabre Richard C | SVP, Chief Accounting Officer | A | 79,000 | $0.00 | $0.00 |
| Jan 30, 2026 | Malabre Richard C | SVP, Chief Accounting Officer | A | 119,000 | $0.00 | $0.00 |
| Jan 30, 2026 | Grund Nicholas | Chief Commercial Officer | A | 204,000 | $0.00 | $0.00 |
| Jan 30, 2026 | Grund Nicholas | Chief Commercial Officer | A | 320,000 | $0.00 | $0.00 |
| Jan 30, 2026 | Butler John P. | CEO and President | A | 743,000 | $0.00 | $0.00 |
| Jan 30, 2026 | Butler John P. | CEO and President | A | 1,115,000 | $0.00 | $0.00 |
2 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 0 mixed, 0 neutral. Avg impact: 7.0/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (91% buy). Based on 11 analysts: 5 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$4.20 mean target
+356.5% upside
Strong Buy (1.25)
$3.00 Low
$6.00 High
| Metric | Value |
|---|---|
| Current Price | $0.9200 |
| Target Low | $3.00 |
| Target Mean | $4.20 |
| Target Median | $4.00 |
| Target High | $6.00 |
| # Analysts | 5 |
| Recommendation | Strong Buy (1.25) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.03 | $-0.03 | $-0.02 | -193.6% | -400.0% | 1↑ 0↓ | $0.0B | -21.8% | 2 |
| Next Q 2026-09-30 |
$-0.03 | $-0.04 | $-0.02 | 0.0% | -700.0% | 1↑ 0↓ | $0.0B | -15.3% | 2 |
| Current FY 2026-12-31 |
$-0.10 | $-0.13 | $-0.08 | -425.0% | -800.0% | 1↑ 0↓ | $0.2B | -12.5% | 2 |
| Next FY 2027-12-31 |
$-0.19 | $-0.20 | $-0.18 | -81.0% | -100.0% | 1↑ 0↓ | $0.2B | -22.6% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.025 | |
| 7d ago | $-0.005 | -0.020 |
| 30d ago | $-0.005 | -0.020 |
| 60d ago | $-0.005 | -0.020 |
| 90d ago | $0.000 | -0.025 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 7, 2026 | BTIG | REITERATE | Buy | Buy |
| Feb 25, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Feb 6, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Feb 6, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 5 | 1 | 0 | 0 | 91% | |
| May 1, 2026 | 5 | 5 | 1 | 0 | 0 | 91% | |
| Apr 1, 2026 | 5 | 5 | 1 | 0 | 0 | 91% | |
| Mar 1, 2026 | 5 | 5 | 1 | 0 | 0 | 91% | |
| Feb 1, 2026 | 5 | 5 | 1 | 0 | 0 | 91% | |
| Jan 1, 2026 | 5 | 5 | 1 | 0 | 0 | 91% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 1, 2026
other
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=48MXc5LuArtbmqfJIFgFqUWuCiA8Nc0PyTyS9v27u
May 29, 2026
short_volume
Short Volume: AKBA — 59.4% short (0.9M / 1.6M)
Short: 941,987 | Exempt: 10,591 | TRF Vol: 1,584,732 | Short Ratio: 59.4% | Off-exchange volume (dark pool + OTC)
May 28, 2026
other
Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
<p>CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Cj43t_2NIZT6s-3bCdwXkO28THhx2JyBtN3zBbQoS-
May 11, 2026
Clinical Trial
To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis
Phase Phase 3 — ACTIVE_NOT_RECRUITING
May 11, 2026
clinical_trial_readout
T-90d Trial Readout: Erythropoiesis-Stimulating Agent (ESA) (Phase 3)
Trial: To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Ce
May 11, 2026
earnings_calendar
AKBA Q1 2026 Earnings Scheduled — 2026-05-11
May 7, 2026
earnings_calendar
AKBA Q1 2026 Earnings Scheduled — 2026-05-07
May 5, 2026
short_volume
Short Volume: AKBA — 57.2% short (0.7M / 1.2M)
Short: 685,001 | Exempt: 1,261 | TRF Vol: 1,197,970 | Short Ratio: 57.2% | Off-exchange volume (dark pool + OTC)
May 4, 2026
clinical_trial_readout
T-90d Trial Readout: Erythropoiesis-Stimulating Agent (ESA) (Phase 3)
Trial: To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Ce
May 3, 2026
clinical_trial_readout
T-90d Trial Readout: Erythropoiesis-Stimulating Agent (ESA) (Phase 3)
Trial: To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Ce
Apr 30, 2026
earnings
Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights
<p align="center">Akebia to Host Conference Call on May 7 at 8:00 a.m. EDT</p>
Apr 30, 2026
short_volume
Short Volume: AKBA — 63.0% short (0.4M / 0.7M)
Short: 424,789 | Exempt: 582 | TRF Vol: 674,458 | Short Ratio: 63.0% | Off-exchange volume (dark pool + OTC)
Apr 24, 2026
short_volume
Short Volume: AKBA — 56.4% short (0.6M / 1.1M)
Short: 607,274 | Exempt: 60 | TRF Vol: 1,077,308 | Short Ratio: 56.4% | Off-exchange volume (dark pool + OTC)
Apr 23, 2026
short_volume
Short Volume: AKBA — 60.5% short (0.7M / 1.2M)
Short: 719,260 | Exempt: 6,142 | TRF Vol: 1,189,249 | Short Ratio: 60.5% | Off-exchange volume (dark pool + OTC)
Apr 21, 2026
short_volume
Short Volume: AKBA — 59.1% short (0.5M / 0.9M)
Short: 533,840 | Exempt: 3,700 | TRF Vol: 903,552 | Short Ratio: 59.1% | Off-exchange volume (dark pool + OTC)
Apr 20, 2026
short_volume
Short Volume: AKBA — 63.0% short (0.6M / 1.0M)
Short: 640,685 | Exempt: 7 | TRF Vol: 1,017,615 | Short Ratio: 63.0% | Off-exchange volume (dark pool + OTC)
Apr 1, 2026
FDA
VAFSEO
Supplemental Approval — Labeling — VADADUSTAT — TABLET — ORAL